Using AI to identify if ovarian tumors are benign or malignant
Official title: Computer-aided Radiology for Cancer Detection and Therapy Stratification - Benign or Malignant Ovarian Tumors.
Run by Gynaecologisch Oncologisch Centrum Zuid · NCT05174377 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing whether a computer program can help doctors tell if ovarian tumors are harmless or cancerous by looking at past CT scans and patient information.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 600 (estimated) |
| Sponsor | Gynaecologisch Oncologisch Centrum Zuid Academic / other |
| Locations | 5 sites (Eindhoven, Brabant and 4 other locations) |
| Trial ID | NCT05174377 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are women with an ovarian tumor whose malignancy status is uncertain and who have undergone surgery with histological confirmation.
✕Probably not a fit
Patients with an indefinite pathology report or insufficient staging information in their surgical reports may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to enhance the accuracy of distinguishing between benign and malignant ovarian tumors using a computer-aided detection algorithm. The research utilizes existing CT-scan images and clinical data from patients who have undergone surgery for ovarian tumors. By employing artificial intelligence techniques, specifically a support vector machine algorithm, the study seeks to improve diagnostic precision and reduce unnecessary referrals to specialized oncology centers. The study is retrospective, analyzing previously established diagnoses to refine the algorithm's effectiveness.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate diagnoses of ovarian tumors, reducing unnecessary surgeries and anxiety for patients.
How similar studies have gone: Other studies utilizing AI in radiology have shown promising results, indicating potential for success in this novel application.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with an ovarian tumor of which it is unknown whether it is benign or malignant (Risk of Malignancy Index (RMI) \>200) * underwent surgery * histological proof of tumor Exclusion Criteria: * indefinite pathology report * lack of correct description of staging in OR report when applicable
Where it's running
-
Catharina hospital
Eindhoven, Brabant, Netherlands Recruiting -
Netherlands Cancer Institute
Amsterdam, Noord Holland, Netherlands Recruiting -
Leiden University Medical Center
Leiden, Noord Holland, Netherlands Recruiting -
Amphia hospital
Breda, Netherlands Recruiting -
Amsterdam medical center
Amsterdam, Netherlands Not yet recruiting
Study contacts
- Study coordinator: Jurgen Piek, MD-PhD
- Email: jurgen.piek@catharinaziekenhuis.nl
- Phone: 040 - 239 91 11
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
CR-002 study in adults with advanced solid tumors
This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors
-
VT-101 in Advanced Ovarian Cancer: early safety study in adults
This early-phase trial tests VT-101 in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer to see if it is safe, how the body handles it, and whether there are any initial signs of activity.
-
Methylation markers in self-samples to help detect gynecological cancers
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
EHR-based approach to boost HBOC genetic testing in at-risk women
A new EHR tool-based program tests whether computer prompts and real patient resources can help more women with family histories of breast or ovarian cancer get HBOC genetic testing.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.